Back to top
more

Elevance Health, Inc. (ELV)

(Real Time Quote from BATS)

$278.38 USD

278.38
947,075

+3.45 (1.26%)

Updated Aug 5, 2025 02:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Charles River (CRL) Q3 Earnings Top Estimates, Margins Dip

by Zacks Equity Research

Headwinds associated with foreign exchange due to the strengthening of the U.S. dollar and interest expense due to a rising interest rate environment increase concerns for Charles River (CRL).

Zacks Equity Research

Zimmer Biomet (ZBH) Q3 Earnings Beat, Gross Margin Falls

by Zacks Equity Research

Each of Zimmer Biomet's (ZBH) geographic segments and product divisions barring S.E.T. and "Other" record year-over-year sales growth at CER.

Zacks Equity Research

CVS Health (CVS) Q3 Earnings Surpass Estimates, View Up

by Zacks Equity Research

Robust sales growth across all three operating segments drive CVS Health's (CVS) top line.

Zacks Equity Research

Hologic (HOLX) Q4 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Lower sales of COVID-19 assays and supply chain challenges drag Hologic's (HOLX) top line down.

Zacks Equity Research

Fresenius Medical's (FMS) Q3 Earnings and Revenues Top

by Zacks Equity Research

Fresenius Medical's (FMS) third-quarter revenues benefit from strong performance across all the geographic regions and segments. However, rising costs hurt margins.

Zacks Equity Research

McKesson (MCK) Q2 Earnings Miss Estimates, Revenues Rise Y/Y

by Zacks Equity Research

McKesson's (MCK) fiscal second-quarter 2023 results benefit from segmental growth.

Zacks Equity Research

Catalent (CTLT) Q1 Earnings Lag Estimates, FY23 View Cut

by Zacks Equity Research

Catalent (CTLT) records robust first-quarter fiscal 2023 results of its Pharma and Consumer Health segment despite overall soft performance.

Zacks Equity Research

IDEXX (IDXX) Q3 Earnings Beat Estimates, 2022 EPS View Down

by Zacks Equity Research

IDEXX's (IDXX) Q3 top-line performance rides on strong CAG Diagnostics recurring revenue growth.

Zacks Equity Research

Stryker's (SYK) Q3 Earnings Miss Estimates, Volume Improves

by Zacks Equity Research

Stryker's (SYK) third-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurt sales growth.

Zacks Equity Research

Ecolab (ECL) Q3 Earnings & Revenues Miss Mark, Margins Down

by Zacks Equity Research

Ecolab's (ECL) robust performance across all its segments drives its Q3 sales, despite business challenges.

Zacks Equity Research

Henry Schein (HSIC) Q3 Earnings In Line, 2022 Sales View Down

by Zacks Equity Research

Severe currency headwinds and lower sales of PPE and COVID-19 test kits affect Henry Schein's (HSIC) top line in Q3.

Zacks Equity Research

Teleflex (TFX) Q3 Earnings Top Estimates, Adjusted EPS View Cut

by Zacks Equity Research

For UroLift, Teleflex (TFX) currently assumes 2022 revenues to be roughly $320 million, down from the prior guidance of $335 million.

Zacks Equity Research

Abiomed (ABMD) Q2 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Abiomed's (ABMD) strength in Impella product revenues drives its Q2 top line.

Zacks Equity Research

ResMed (RMD) Q1 Earnings In Line, Operating Margin Falls

by Zacks Equity Research

ResMed (RMD) continues to increase its access to semiconductor communications chips.

Zacks Equity Research

Amedisys (AMED) Q3 Earnings Miss Estimates, Guidance Cut

by Zacks Equity Research

Within Amedisys (AMED) Home Health and Hospice, the reinstatement of sequestration reduces growth in Q3.

Zacks Equity Research

Avantor (AVTR) Q3 Earnings Top Estimates, 2022 EPS View Cut

by Zacks Equity Research

Avantor's (AVTR) robust performance across the majority of its segments drives its Q3 sales, despite business challenges.

Zacks Equity Research

Edwards Lifesciences (EW) Q3 Earnings Miss, Margins Rise

by Zacks Equity Research

Edwards Lifesciences (EW) continues to register strong momentum in TMTT on a portfolio of differentiated therapies, positive pivotal trial results and favorable real-world clinical outcomes.

Zacks Equity Research

Bio-Rad (BIO) Q3 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

Bio-Rad's (BIO) third-quarter revenues decline mainly as a result of lower COVID-related sales compared with the year-ago period.

Zacks Equity Research

DexCom (DXCM) Q3 Earnings Beat Estimates, Guidance Revised

by Zacks Equity Research

DexCom's (DXCM) third-quarter results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

Zacks Equity Research

Integer Holdings (ITGR) Q3 Earnings Beat, 2022 View Lowered

by Zacks Equity Research

Integer Holdings' (ITGR) third-quarter results reflect robust Medical and Non-Medical Sales, besides strength in all the product lines.

Zacks Equity Research

DaVita (DVA) Q3 Earnings Lag Estimates, 2022 EPS View Cut

by Zacks Equity Research

DaVita's (DVA) Q3 performance gets a boost from strength in both its segments.

Zacks Equity Research

Baxter (BAX) Q3 Earnings Meet Estimates, Hilrom Adds $735 M

by Zacks Equity Research

Baxter's (BAX) third-quarter results reflect the robust performance of the Medication Delivery business unit and Hilrom's businesses.

Zacks Equity Research

LabCorp (LH) Misses Q3 Earnings Estimates, Updates Guidance

by Zacks Equity Research

LabCorp's (LH) organic revenues decline significantly, mainly due to major decrease in COVID-19 PCR and antibody testing sales.

Zacks Equity Research

Merit Medical (MMSI) Q3 Earnings Beat, FY22 View Revised

by Zacks Equity Research

Merit Medical (MMSI), in the third quarter, benefits from revenue growth in both its segments and the majority of product categories within its Cardiovascular unit.

Zacks Equity Research

Integra's (IART) Q3 Earnings Top, Gross Margin Declines

by Zacks Equity Research

Integra (IART) notices recovery in procedure volumes leading to solid growth across most of its product portfolio in Q3.